Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Halozyme Therapeutics
HALO
5
Precision Drilling
PDS
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 96.85%-157.85K | 782.77%850.2K | 6.54%-1.67M | 197.79%1.64M | 30.99%-983.23K | -24.58%-5.02M | 68.30%-124.52K | 6.72%-1.79M | 33.74%-1.68M | -274.11%-1.42M |
Net income from continuing operations | 48.34%-12.6M | 79.60%-1.96M | -125.00%-8.69M | 79.59%-1.62M | 89.00%-326.77K | -410.38%-24.4M | -397.85%-9.6M | -194.52%-3.86M | -4,554.29%-7.96M | -72.85%-2.97M |
Operating gains losses | -100.23%-5K | --0 | --0 | --0 | -104.47%-5K | 1,587.09%2.14M | 1,994.10%1.85M | -43.52%50.96K | 1,219.71%129.89K | 379.81%111.93K |
Depreciation and amortization | 5.71%2.38M | -0.63%636.78K | 18.86%636.78K | 2.16%555.69K | 3.75%553.1K | 28.69%2.25M | 27.51%640.84K | 28.83%535.74K | 27.82%543.94K | 30.91%533.1K |
Deferred tax | 64.20%87.85K | 291.86%72.41K | -123.74%-7.37K | -102.18%-720 | -13.13%23.54K | -69.77%53.5K | -124.30%-37.74K | 329.96%31.06K | 358.00%33.09K | 275.11%27.1K |
Other non cash items | 1,077.95%1.81M | -62.96%37.44K | 7.39%14.21K | -245.88%-20.05K | 6,772.75%1.78M | 132.78%153.97K | 333.75%101.07K | -92.71%13.23K | 102.85%13.74K | 120.51%25.93K |
Change In working capital | 34.15%-644.85K | 935.14%1.82M | -161.98%-1.5M | 283.90%2.35M | -576.98%-3.32M | 62.36%-979.22K | 168.51%175.66K | 59.92%-571.24K | 57.20%-1.28M | -66.37%696.03K |
-Change in receivables | 362.17%1.75M | 139.65%928.08K | 225.32%822.78K | 4,392.63%1.74M | -176.06%-1.74M | -23.65%-667.17K | -212.45%-2.34M | 50.53%-656.56K | 111.27%38.76K | 21.83%2.29M |
-Change in payables and accrued expense | -395.73%-4.41M | -73.10%735.39K | -984.06%-1.5M | 349.47%915.33K | -337.25%-4.57M | 59.49%1.49M | 891.97%2.73M | -78.43%169.43K | 38.27%-366.91K | -322.64%-1.04M |
-Change in other current assets | 103.08%33.59K | 2,638.47%121.87K | 72.84%-45.89K | 107.15%41.92K | 74.50%-84.31K | 27.26%-1.09M | -104.80%-4.8K | 83.33%-168.93K | -20.79%-586.36K | -228.68%-330.6K |
-Change in other current liabilities | 605.09%3.1M | 66.71%437.34K | -414.59%-669.68K | 49.84%-208.5K | 625.93%3.54M | -9.44%-612.88K | -53.24%262.33K | -47.74%212.87K | 70.29%-415.66K | -419.46%-672.42K |
-Change in other working capital | -1,004.12%-1.11M | 14.85%-404.34K | 17.29%-105.91K | -370.61%-136.65K | -202.62%-463.65K | 89.28%-100.58K | -6.97%-474.85K | 53.85%-128.05K | 130.21%50.5K | 1,007.29%451.82K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 96.85%-157.85K | 782.77%850.2K | 6.54%-1.67M | 197.79%1.64M | 30.99%-983.23K | -24.58%-5.02M | 68.30%-124.52K | 6.72%-1.79M | 33.74%-1.68M | -274.11%-1.42M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 45.82%-2.46M | 100.00%-2 | -10,523.51%-1.32M | 42.71%-4.54M | 4.88%-4.52M | 98.58%-12.44K | ||||
Net PPE purchase and sale | 94.79%-1.51K | 99.97%-2 | --0 | ---- | ---- | 59.84%-29K | 8.17%-7.1K | -172.73%-12.44K | ---- | ---- |
Net business purchase and sale | 73.68%-1.19M | --0 | ---- | ---- | ---- | 4.87%-4.51M | ---4.51M | ---- | ---- | ---- |
Net other investing changes | ---1.27M | --0 | ---135K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 45.82%-2.46M | 100.00%-2 | -10,523.51%-1.32M | ---- | ---- | 42.71%-4.54M | 4.88%-4.52M | 98.58%-12.44K | ---- | ---- |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -57.81%4.18M | -18.18%1.69M | -107.13%-270.98K | 119.03%1.83M | -70.91%934.96K | -9.13%9.92M | -69.31%2.07M | 480.82%3.8M | -31.96%833.92K | 40.36%3.21M |
Net issuance payments of debt | -52.78%3.03M | 125.88%542.13K | -106.84%-270.98K | 42.62%1.63M | -66.75%1.13M | 12.48%6.42M | -322.71%-2.09M | 505.84%3.96M | -37.53%1.14M | 49.10%3.41M |
Net common stock issuance | -71.54%1.19M | ---- | ---- | ---- | ---- | -28.24%4.16M | ---- | ---- | ---- | ---- |
Cash dividends paid | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 |
Net other financing activities | 94.98%-33.67K | ---- | ---- | ---- | ---- | -11.71%-670.26K | --0 | ---163.68K | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -57.81%4.18M | -18.18%1.69M | -107.13%-270.98K | 119.03%1.83M | -70.91%934.96K | -9.13%9.92M | -69.31%2.07M | 480.82%3.8M | -31.96%833.92K | 40.36%3.21M |
Net cash flow | ||||||||||
Beginning cash position | 5.04%7.56M | -35.00%6.58M | 21.13%9.85M | -16.40%7.51M | 5.04%7.56M | -12.55%7.2M | 81.13%10.13M | 5.20%8.13M | -11.60%8.99M | -12.55%7.2M |
Current changes in cash | 332.19%1.57M | 198.99%2.54M | -263.01%-3.26M | 372.35%2.33M | -102.70%-48.27K | 135.13%362.84K | -260.13%-2.57M | 193.75%2M | 64.85%-857.17K | -7.59%1.79M |
End cash Position | 20.74%9.13M | 20.74%9.13M | -35.00%6.58M | 21.13%9.85M | -16.40%7.51M | 5.04%7.56M | 5.04%7.56M | 81.13%10.13M | 5.20%8.13M | -11.60%8.99M |
Free cash flow | 96.84%-159.36K | 745.93%850.2K | 7.19%-1.67M | 197.15%1.64M | 30.99%-983.23K | -23.09%-5.05M | 67.14%-131.62K | 6.29%-1.8M | 34.46%-1.69M | -277.97%-1.42M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |